CTLA4 and cancer: As discussed in Section 6, while immune checkpoint inhibitors targeting PD-L1 and CTLA-4 have transformed cancer immunotherapy, they can cause immune-related adverse effects like fatigue, skin rashes, endocrine disorders, and hepatic toxicities (108, 109).